Opendata, web and dolomites

Quality2Cells

TimeLapseReader for Quality Control of Immune Cells used for Cell-Based Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Quality2Cells project word cloud

Explore the words cloud of the Quality2Cells project. It provides you a very rough idea of what is the project "Quality2Cells" about.

eminent    ctb    culture    patient    manufacturing    solution    business    innovation    efficient    plan    kits    disruptive    personalized    thousands    elicit    treat    reproducible    immune    version    quality    medicine    ready    player    migration    assuming    ibidi    strategy    freedom    patients    combination    timelapsereader    assays    hundred    actively    ce    validate    automated    approval    cbt    identification    market    provider    complete    cells    final    standard    cure    cured    marking    adverse    operate    15    regarding    transform    carriers    treatment    feasibility    worldwide    tumours    strives    qc    risks    cancer    remaining    live    enter    regulatory    types    migrating    motility    competitor    facilities    cell    serval    device    instrument    millions    setting    slides    consolidate    therapy    therapeutic    global    20    inactive    standardized    entry    explore    medical    obtain    difficult    reagents    expensive    bench    tests   

Project "Quality2Cells" data sheet

The following table provides information about the project.

Coordinator
IBIDI GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG MARTINSRIED
postcode: 82152
website: www.ibidi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.ibidi.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBIDI GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine. However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks. In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects. Yet, there is no quality control (QC) regarding motility of therapeutic cells before patient treatment. The goal of the proposal is to promote an integrated bench-top instrument for reliable assessment of motility parameters in standardized cell culture carriers, i.e. the TimeLapseReader.

As leading provider of live cell migration assays ibidi strives to market a complete QC solution based on an automated instrument in combination with ready-to-use QC kits, slides and reagents. The TimeLapseReader will allow robust and reproducible migration tests in manufacturing facilities and set a new standard for QC of immune cell in CBT.

In Phase 1 the feasibility study will explore key parameters for QC in the most relevant therapeutic cell types and the best market entry strategy. Objectives include: • Identification of relevant QC parameters for therapeutic cells. • Setting up the business plan including competitor and freedom-to-operate analysis. • Strategy to obtain regulatory approval / CE-Marking for the final device version.

Expected impact is eminent as CBT is going to enter the medical market with serval hundred to thousands of patients treated worldwide per year. It is expected, that up to 20% of all cancer patients can be cured with CTB within 10-15 years assuming serval millions QC per year. ibidi will apply for funding to validate QC tests in a Phase 2 proposal. Phase 2 will consolidate the technology and transform ibidi into a global player of medical QC in the CBT field.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUALITY2CELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUALITY2CELLS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More